Alisha H. Bent, M.D.

Peer-Reviewed Articles

1. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. PMID: 38085001.
2. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. e-Pub 2023. PMID: 37738316.
3. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022.
4. Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clin Genitourin Cancer 17(2):e263-e272, 2019. e-Pub 2018. PMID: 30538068.
5. Buran TJ, Sandhu AK, Azeredo AM, Bent AH, Williamson JG, Gu L. Effects of exogenous abscisic acid on fruit quality, antioxidant capacities, and phytochemical contents of southern high bush blueberries. Food Chem 132(3):1375-1381, 2012. e-Pub 2011. PMID: 29243625.

Other Articles

1. Bent, A & Kopetz, S Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clinical Cancer Research 27(20), 2021.

Abstracts

1. Arvind Dasari, Alisha Bent, Kristin Alfaro-Munoz, Ryan Huey, Benny Johnson, Michael Lee, Maria Pia Morelli, Van Morris, Michael Overman, Christine Parseghian, Kanwal Raghav, John Shen, Jason Willis, Timothy Newhook, Abhineet Uppal, Y. Nancy You, Tsuyoshi Konishi, George Chang, Scott Kopetz, Robert Wolff. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. Journal of Clinical Oncology, 2023.
2. Bent, A. H., Maru, D. M., Vauthey, J., Dasari, A., Johnson, B., Kee, B. K., ... & Raghav, K. P. S.. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. Journal of Clinical Oncology, 2022.
3. Bowman, A., Bent, A., Le, T., Christie, A., Wardak, Z., Bruce Mickey, S., Timmerman, R., Hannan, R., Brugarolas, J.. Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches. Journal of Clinical Oncology, 2018.
4. Bosse, D., Xie, W., Wells, C., Lalani, A., Donskov, F., Bent AH., Sim, H., Beuselinck, B., Bamias, A., Porta, C., Vaishampayan, U., Pal, S., Agarwal, N., Srinivas, S., Rini, B., Alva, A., Wood, L., Kapoor, A., Choueiri, T., Chin Heng, D.. Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). Journal of Clinical Oncology, 2017.

Book Chapters

1. Parseghian, C., Bent, A. Colorectal Liver Metastases. In: Targeted Therapy Beyond EGFR and VEGF. Spring Nature, 2021.